Form 4: Charles River Laboratories Executive Birgit Girshick Reports Acquisition of Restricted Stock Units

Birgit Girshick, Corporate Executive VP & COO of Charles River Laboratories International, Inc., reported the acquisition of 12,239 restricted stock units and the subsequent disposal of 283 shares for tax withholding purposes.

Summary

• Birgit Girshick, Corporate Executive VP & COO of Charles River Laboratories International, Inc. (CRL), acquired 12,239 shares of common stock on May 30, 2025, at a price of $135.63 per share.
• These acquired shares are unvested restricted stock units, which will vest annually on May 30, 2026, May 30, 2027, May 30, 2028, and May 30, 2029.
• On May 31, 2025, Ms. Girshick disposed of 283 shares of common stock at $135.63 per share, which is indicated as a transaction for the payment of tax liability.
• Following these transactions, Ms. Girshick beneficially owns 65,944 shares of common stock directly.
• The filing indicates that the transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The sentiment is positive as it reflects an executive receiving compensation in the form of equity, aligning their interests with shareholders. The disposal for tax is a standard, neutral event.

Positives

• The acquisition of 12,239 restricted stock units by a key executive, Birgit Girshick, aligns her interests with long-term shareholder value.
• The transaction is part of a compensation plan, indicating ongoing executive retention and motivation.

Negatives

• A portion of the acquired shares (283 shares) was immediately disposed of to cover tax liabilities, which is a common practice but reduces the net shares held.

Future Outlook

The acquired restricted stock units are unvested and will vest annually on May 30th from 2026 through 2029, indicating a long-term incentive structure for the executive.

Management Comments

• The filing indicates that the transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

This Form 4 filing is a routine disclosure of executive compensation and stock ownership, common across all industries, including the pharmaceutical and biotechnology services sector where Charles River Laboratories operates. It does not provide specific industry-wide trends or competitive insights.

Stakeholder Impact

• Shareholders: The grant of restricted stock units to a key executive can be seen as a positive for corporate governance, aligning management incentives with long-term shareholder value. The issuance of new shares for compensation may result in minor dilution, but this is standard for equity compensation plans.
• Employees: This filing specifically pertains to executive compensation and does not directly impact the broader employee base, though it reflects the company's compensation practices for senior leadership.

Next Steps

• Annual vesting of the restricted stock units on May 30, 2026, May 30, 2027, May 30, 2028, and May 30, 2029.

Key Dates

Keywords

Charles River Laboratories, CRL, Birgit Girshick, SEC Form 4, Insider Transaction, Restricted Stock Units, Executive Compensation, Stock Ownership, Biotechnology, Pharmaceutical Services